Astrazeneca (AZN) Revenue (2006 - 2026)
Astrazeneca (AZN) revenue from Mar 31, 2006 to Mar 31, 2026. The TTM Astrazeneca (AZN) revenue is $60B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Revenue
Quarterly Revenue
Astrazeneca (AZN) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +9.93% |
| 3 Years TTM | +11.30% |
| 5 Years TTM | +16.99% |
| 10 Years TTM | +9.33% |
| All Time TTM | +4.28% |
Annual Revenue change of Astrazeneca (AZN)
| Year | Revenue | Change |
|---|---|---|
| 2026 | $15B | -73.97% |
| 2025 | $59B | +8.63% |
| 2024 | $54B | +18.03% |
| 2023 | $46B | +3.29% |
| 2022 | $44B | +18.53% |
| 2021 | $37B | +40.58% |
| 2020 | $27B | +9.16% |
| 2019 | $24B | +10.38% |
| 2018 | $22B | -1.67% |
| 2017 | $22B | -2.33% |
| 2016 | $23B | -6.90% |
| 2015 | $25B | -6.93% |
| 2014 | $27B | +2.87% |
| 2013 | $26B | -7.75% |
| 2012 | $28B | -16.72% |
| 2011 | $34B | +0.97% |
| 2010 | $33B | +1.42% |
| 2009 | $33B | +3.81% |
| 2008 | $32B | +6.91% |
| 2007 | $30B | +11.65% |
| 2006 | $26B | N/A |
Comparison Astrazeneca (AZN) five years revenue CAGR with competitors
Astrazeneca (AZN) five years revenue CAGR is 16.99%.
| Ticker | Name | five years Revenue CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 23.17% | +36.41% |
| NVO | Novo Nordisk | 20.75% | +22.14% |
| MRK | Merck & Co Inc | 10.41% | -38.73% |
| AMGN | AMGEN Inc | 8.14% | -52.06% |
| PFE | Pfizer Inc | 6.56% | -61.38% |
| GRFS | Grifols SA | 5.39% | -68.24% |
| SNY | Sanofi | 5.03% | -70.40% |
| ABBV | Abbvie Inc | 4.59% | -72.98% |
| GILD | Gilead Sciences Inc | 3.07% | -81.93% |
| JNJ | Johnson & Johnson | 2.73% | -83.92% |
| BMY | Bristol-Myers Squibb Company | 2.52% | -85.17% |
| NVS | Novartis AG | 2.36% | -86.11% |
| GSK | GSK Plc | 0.63% | -96.28% |